MX9304089A - Uso de gm-csf como una vacuna adyuvante. - Google Patents

Uso de gm-csf como una vacuna adyuvante.

Info

Publication number
MX9304089A
MX9304089A MX9304089A MX9304089A MX9304089A MX 9304089 A MX9304089 A MX 9304089A MX 9304089 A MX9304089 A MX 9304089A MX 9304089 A MX9304089 A MX 9304089A MX 9304089 A MX9304089 A MX 9304089A
Authority
MX
Mexico
Prior art keywords
csf
vaccine
adjuvant vaccine
mammal
effective amount
Prior art date
Application number
MX9304089A
Other languages
English (en)
Inventor
Eric M Bonnem
Imtiaz A Chaudry
Elliot Stupak
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX9304089A publication Critical patent/MX9304089A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención es un método para realzar la respuesta inmune de un mamífero a una vacuna que consta de la administración a tal mamífero de una cantidad efectiva de GM-CSF en conjunción con una vacuna. La presente invención además proporciona una composición farmacéutica que consta de una cantidad efectiva de GM-CSF, un antígeno natural, sintético o recombinante y un transportador farmacéuticamente aceptable.
MX9304089A 1992-07-08 1993-07-07 Uso de gm-csf como una vacuna adyuvante. MX9304089A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91039992A 1992-07-08 1992-07-08

Publications (1)

Publication Number Publication Date
MX9304089A true MX9304089A (es) 1994-01-31

Family

ID=25428728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304089A MX9304089A (es) 1992-07-08 1993-07-07 Uso de gm-csf como una vacuna adyuvante.

Country Status (11)

Country Link
US (1) US5679356A (es)
EP (1) EP0651656A1 (es)
JP (1) JPH07504683A (es)
CN (1) CN1091978A (es)
AU (1) AU4662393A (es)
CA (1) CA2139756A1 (es)
IL (1) IL106280A0 (es)
MX (1) MX9304089A (es)
TN (1) TNSN93075A1 (es)
WO (1) WO1994001133A1 (es)
ZA (1) ZA934890B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
EP0741580A4 (en) * 1993-12-14 2001-07-11 Univ Johns Hopkins Med CONTROLLED RELEASE OF PHARMACEUTICALLY ACTIVE SUBSTANCES FOR IMMUNOTHERAPY
JPH09509828A (ja) * 1994-03-04 1997-10-07 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 標的遺伝子損傷をした動物
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US8791237B2 (en) * 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US6060258A (en) * 1995-09-28 2000-05-09 Otsuka Pharmaceutical Co., Ltd. Neutrophil chemotactic lymphokine, and method for the diagnosis of drug hypersensitive granulocytopenia using the same
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6153182A (en) * 1997-12-19 2000-11-28 Uab Research Foundation Lymphotactin as an adjuvant
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7611721B1 (en) 1999-05-13 2009-11-03 Wyeth Holdings Corporation Adjuvant combination formulations
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
US6541458B1 (en) * 1999-07-16 2003-04-01 Merial Feline calicivirus genes and vaccines in particular recombinant vaccines
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
AT409086B (de) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
FR2810888B1 (fr) * 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
KR20030064377A (ko) * 2000-08-11 2003-07-31 파브릴, 인크. Ｔ 세포 매개 병증을 개선시키기 위한 방법 및 조성물
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
AU2002232560A1 (en) 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
MXPA03004071A (es) 2000-11-10 2003-09-04 Wyeth Corp Formulaciones de combinacion de adyuvantes.
PE20020572A1 (es) 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
JPWO2003028758A1 (ja) * 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
AU2002363322A1 (en) * 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
EP1374893A1 (en) 2002-06-17 2004-01-02 NovImmune S.A. Vaccination with immuno-isolated cells producing an immunomodulator
US6809191B2 (en) * 2002-07-03 2004-10-26 Vaxim, Inc. GM-CSF nucleic acid sequences
KR20070006668A (ko) * 2003-10-14 2007-01-11 추가이 세이야쿠 가부시키가이샤 신장 질환 치료제
JP2008526763A (ja) * 2004-12-29 2008-07-24 マンカインド コーポレイション 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法
WO2006116053A1 (en) * 2005-04-22 2006-11-02 Sciclone Pharmaceuticals, Inc. Immunomodulator compounds as vaccine enhancers
WO2007055952A2 (en) * 2005-11-03 2007-05-18 Wyeth Process for producing stable hiv th-ctl peptides
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US9598462B2 (en) 2012-01-26 2017-03-21 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP2772267B1 (en) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
CA2701168A1 (en) 2007-10-01 2009-07-09 Longhorn Vaccines & Diagnostics, Llc Biological specimen collection and transport system and methods of use
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
MX2010005718A (es) 2007-11-28 2010-08-10 Irx Therapeutics Inc Metodo para incrementar el efecto inmunologico.
ES2588183T3 (es) * 2009-03-31 2016-10-31 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Procedimiento para la prevención de la gripe utilizando una vacuna para administración intranasal
MX2011012147A (es) 2009-05-15 2012-06-19 Irx Therapeutics Inc Inmunoterapia de vacuna.
CN107050430B (zh) 2009-12-08 2021-10-15 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
CN102946900A (zh) 2010-03-11 2013-02-27 免疫设计公司 用于大流行流感的疫苗
US20120263754A1 (en) 2011-02-15 2012-10-18 Immune Design Corp. Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
DK2850431T3 (en) 2012-05-16 2018-07-16 Immune Design Corp Vaccines against HSV-2
RU2662685C2 (ru) 2013-09-25 2018-07-26 Зоэтис Сервисиз Ллс Pcv2b дивергентная вакцинная композиция и способы её применения
KR20160105813A (ko) 2014-01-21 2016-09-07 이뮨 디자인 코포레이션 알레르기성 병태의 치료에 사용하기 위한 조성물
US20160058852A1 (en) 2014-02-14 2016-03-03 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
JP6836400B2 (ja) 2014-03-28 2021-03-03 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション 乳がんおよび卵巣がんワクチン
MX2017000630A (es) 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
AU2015342939A1 (en) * 2014-11-07 2017-05-18 Wisconsin Alumni Research Foundation Targeting DNA vaccines to B cells
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
RU2727697C2 (ru) 2015-09-25 2020-07-23 Максивакс Са Вакцинация с использованием иммуно-изолированных клеток, продуцирующих иммуномодулятор
WO2018231706A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
EP3843782A1 (en) 2018-08-29 2021-07-07 Centre Hospitalier Universitaire Vaudois (CHUV) Ebola vaccine compositions and methods of using same
TW202134430A (zh) 2019-12-03 2021-09-16 美商紐沃進公司 腫瘤細胞疫苗
EP4126029A1 (en) 2020-03-23 2023-02-08 Loyola University of Chicago Coronavirus vaccine compositions and methods of using same
US20220152169A1 (en) 2020-11-02 2022-05-19 Neuvogen, Inc. Colorectal cancer tumor cell vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
JPH0725688B2 (ja) * 1986-03-31 1995-03-22 住友製薬株式会社 Ｃｓｆ徐放性製剤
AU651949B2 (en) * 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines

Also Published As

Publication number Publication date
ZA934890B (en) 1994-04-14
JPH07504683A (ja) 1995-05-25
EP0651656A1 (en) 1995-05-10
IL106280A0 (en) 1993-11-15
CA2139756A1 (en) 1994-01-20
US5679356A (en) 1997-10-21
CN1091978A (zh) 1994-09-14
AU4662393A (en) 1994-01-31
WO1994001133A1 (en) 1994-01-20
TNSN93075A1 (fr) 1994-03-17

Similar Documents

Publication Publication Date Title
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
ES2092306T3 (es) Adyuvante para vacunas.
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
ES2196024T3 (es) Vacunas conjugadas de gangliosido-klh con qs-21.
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
ES8802275A1 (es) Un metodo para preparar una vacuna pra inducir inmunidad a la tosferina.
ES2061851T3 (es) Formulaciones intranasales de calcitonina.
NL300187I1 (nl) Acellulair vaccin.
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
OA09672A (en) Use of il-4 to enhance immune response to infectious antigenic challenges
MY128929A (en) Vaccine against hepatitis a and hepatitis b
IT1217314B (it) Nonapeptide sintetico ad attivita'adiuvante capace di potenziare in vivo la risposta anticorporale
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
AR012896A1 (es) Polipeptido flge de helicobacter pylori, composicion de vacuna, uso de dicho polipeptido para la fabricacion de composiciones, metodo de diagnostico invitro, y kit de diagnostico para la deteccion de la infeccion por helicobacter pylori
MX9707295A (es) Metodo para mejorar la respuesta de los anticuerpos a los antigenos especificos con interleucina-10.
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
ECSP972211A (es) Nueva composicion de vacuna y su uso en la medicina, especialmente para prevenir infecciones de paludismo